coagulation analyzer Market

The coagulation analyzers market is expected to grow from US$ 4,183.71 million in 2022 to US$ 6,690.08 million by 2030; it is estimated to grow at a CAGR of 6.0% from 2022 to 2030.

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of blood disorders and rising incidence of cardiovascular diseases are driving the coagulation analyzers market size and growth. Additionally, development of point-of-care (POC) coagulation analyzers is likely to emerge as a significant trend in the market during the forecast period. However, high costs and stringent regulations associated with coagulation analyzers hinders market growth during the forecast period 2022-2030.

Cardiovascular diseases (CVDs) cause millions of deaths every year worldwide. The major causes of CVDs are hypertension, obesity, and diabetes. According to the 2022 Heart Disease & Stroke Statistical Update Fact Sheet, Global Burden of Disease, approximately 119.1 million people died of CVDs in 2020. It also stated that the global prevalence of stroke and ischemic stroke in 2020 was 89.1 million and 68.2 million, respectively. As per the National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, ~697,000 people died of heart diseases in the US, i.e., 1 out of every 5 deaths. According to the American Heart Association, over 130 million, or 45.1% of Americans, are likely to acquire some form of CVD by 2035. Further, CVDs majorly cause mortality and morbidity in Europe, accounting for 45% of deaths in the region and 37% in the European Union (EU) each year. High blood pressure is the major risk factor causing CVDs in low-and middle-income countries, resulting in more than 75% of death cases. As per the study 'Global Burden of Disease Study 2019,' CVDs were the leading cause of death in Asia Pacific in 2019, causing 10.8 million or 35% of the total fatalities.

In addition, according to the American College of Cardiology, ~1.2 million angioplasties are performed each year. Similarly, there is an increasing coronary artery bypass grafting (CABG) due to rising incidences of coronary artery disease, myocardial infections, sedentary lifestyles, and hypertension. Further, ~400,000 CABG surgeries are performed each year globally. In the US, ~200,000 CABG surgeries are performed, as per research published in NLM in 2022. In addition, a coagulation test can help prevent potentially heart attack-causing blood clots. A coagulation analyser is used during coronary artery bypass surgery and angioplasty to monitor information about blood clotting status. Thus, the increasing incidence of cardiovascular diseases is driving the growth of the coagulation analyzer market.

?

Increasing Organic and Inorganic Strategies by Key Players

In recent years, changing lifestyle habits and growing geriatric population are increasing the incidence of various types of blood disorders. Thus, there is an increasing demand for early diagnosis and treatment of blood disorders. To enhance the quality of life of people suffering from hemorrhagic disease, key players are taking several initiatives through various organic and inorganic strategies.

- In 2019, Nihon Kohden announced the plan to establish a hematology analyser reagent factory in Dubai.

- In October 2021, Trivitron Healthcare, a medical devices company, launched a new line of coagulation analyser products manufactured by Diagon Ltd in India.

- In June 2021, Trivitron Healthcare introduced NANO H5 and NANO H110 that monitor diabetes, thalassemia, and hemoglobin variations.

- In February 2021, Siemens Healthineers and Sysmex Corporation renewed their long-standing agreement for the global supply, distribution, sales, and service of hemostasis products, which included an extension for multiple years. Further, Siemens Healthineers will distribute Sysmex's automated blood coagulation analyzer, including the CN-3000 and CN-6000, as part of their agreement. Laboratories are provided with these machines, the next generation of fully automated coagulation testing solutions.

- In July 2020, Sysmex Corporation launched the Automated Blood Coagulation Analyzers CN-6500/CN-3500 in Japan. In addition to the blood coagulation and platelet aggregation parameters, it also measures thrombosis and hemostasis parameters.

- In February 2018, Horiba, a Japanese manufacturer of precision instruments for measurement and analysis, launched the Yumizen G, a range of semiautomatic to fully automatic hemostasis solutions for clinical testing.

- In May 2018, Beckman Coulter company launched the DxH 900 hematology analyser, which performs complete blood count and differential white blood cell tests with minimal repeats for use in mid-to high-volume clinical laboratories.

Thus, the key market players are adopting various organic and inorganic strategies, which are anticipated to provide additional opportunities for the growth of the coagulation analyzer market during the forecast period.

The coagulation analyzers market is segmented on the basis of product type, test, technology, and end user. The clinical laboratory analyzers is further sub-bifurcated into system and consumables. The clinical laboratory analyzers segment held the largest market share in 2022. On the other hand, point-of-care testing analyzers accounted significant CAGR for the coagulation analyzers market. Based on test type, the coagulation analyzers market is segmented as prothrombin time testing, fibrinogen testing, D-dimer testing, platelets function testing, activated clotting time testing, activated partial thromboplastin time testing, and others. The prothrombin time testing segment accounted largest market share in 2022. Moreover, the D-dimer testing segment is expected to grow at the highest CAGR during the forecast period. By technology, the coagulation analyzer market is segmented as optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment accounts the largest coagulation analyzers market share in 2022. By application, the coagulation analyzers market is segmented into clinical laboratories, hospitals, and others. The clinical laboratories segment held the highest market share in 2022 and the same segment will register highest CAGR during the forecast period.

Various organic and inorganic strategies are adopted by companies in the coagulation analyzers market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the coagulation analyzers market are listed below.

National Center for Biotechnology Information, Global Burden of Disease, National Library of Medicine, are a few of the major primary and secondary sources referred to while preparing the report on the coagulation analyzers market.